Biological Evaluation of 99mTc-Labeled Cyclic Glycoprotein IIb/IIIa Receptor Antagonists in the Canine Arteriovenous Shunt and Deep Vein Thrombosis Models: Effects of Chelators on Biological Properties of [99mTc]Chelator−Peptide Conjugates
- 1 January 1996
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 7 (2), 203-208
- https://doi.org/10.1021/bc9500960
Abstract
A series of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists, [99mTcO(L1−III)]-, [99mTcO(L6−III)]-, [99mTcO(L1−V)]-, and [99mTcO(L6−V)]-, were evaluated in a canine arteriovenous (AV) shunt model for their potential use as thrombus imaging agents. The thrombus formed consists of a platelet-rich head and a fibrin-rich tail. All four agents were incorporated into the growing thrombus under both arterial (platelet-rich) and venous (platelet-poor) conditions. The rank order for uptake was [99mTcO(L1−V)]- > [99mTcO(L6−V)]- > [99mTcO(L6−III)]- > [99mTcO(L1−III)]- (arterial range, 5.8−0.47 % id/g; venous range, 0.58−0.04 % id/g). The uptakes of both [99mTcO(L6−III)]- and [99mTcO(L1−III)]- under both arterial and venous conditions were not significantly greater than that of [99mTc]albumin and [125I]fibrinogen. In contrast, the uptakes of both [99mTcO(L1−V)]- and [99mTcO(L6−V)]- were significantly greater than those of [99mTc]albumin and [125I]fibrinogen and comparable to that of [111In]platelets under both arterial and venous conditions. All four [99mTc]chelator−peptide conjugates are cleared faster than the controls with the clearance of the conjugates of peptide III faster than that of the conjugates of peptide V. The differences in incorporation are attributable to the effect of both the cyclic peptide and the chelator. The conjugate [99mTcO(L1−V)]- was also studied using a canine DVT (deep vein thrombosis) model. [99mTcO(L1−V)]- was actively incorporated into the growing thrombus with images clearly detectable within 15 min postinjection. At 2 h postinjection, thrombus/blood and thrombus/muscle ratios [region of interest (ROI)/background] were approximately 7/1 and 10/1, respectively. This clearly demonstrated that the conjugate [99mTcO(L1−V)]- has the potential for rapid diagnosis of thrombolic events occurring under both arterial and venous conditions.Keywords
This publication has 4 references indexed in Scilit:
- Labeling Cyclic Glycoprotein IIb/IIIa Receptor Antagonists with 99mTc by the Preformed Chelate Approach: Effects of Chelators on Properties of [99mTc]Chelator−Peptide ConjugatesBioconjugate Chemistry, 1996
- Radiopharmaceuticals for thrombus detectionSeminars in Nuclear Medicine, 1990
- Antithrombotic therapy after myocardial reperfusion in acute myocardial infarctionJournal of the American College of Cardiology, 1988
- Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation.Journal of Biological Chemistry, 1985